ES2101237T3 - Factor-4 plaquetario modificado. - Google Patents

Factor-4 plaquetario modificado.

Info

Publication number
ES2101237T3
ES2101237T3 ES93307592T ES93307592T ES2101237T3 ES 2101237 T3 ES2101237 T3 ES 2101237T3 ES 93307592 T ES93307592 T ES 93307592T ES 93307592 T ES93307592 T ES 93307592T ES 2101237 T3 ES2101237 T3 ES 2101237T3
Authority
ES
Spain
Prior art keywords
factor
mpf
platelets
cpf
waste
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES93307592T
Other languages
English (en)
Inventor
Shalley Kant Gupta
Jai Pal Singh
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Application granted granted Critical
Publication of ES2101237T3 publication Critical patent/ES2101237T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/521—Chemokines
    • C07K14/522—Alpha-chemokines, e.g. NAP-2, ENA-78, GRO-alpha/MGSA/NAP-3, GRO-beta/MIP-2alpha, GRO-gamma/MIP-2beta, IP-10, GCP-2, MIG, PBSF, PF-4, KC
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Saccharide Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Materials For Medical Uses (AREA)

Abstract

LA INVENCION SE BASA EN EL DESCUBRIMIENTO DE DOS FORMAS MODIFICADAS DEL FACTOR 4 DE LAS PLAQUETAS HUMANAS, AQUI LLAMADAS MPF-4 Y CPF-4, QUE FUERON AISLADAS A PARTIR DE UN MEDIO DE CULTIVO LIBRE DE SUERO DE LEUCOCITOS DE LA SANGRE PERIFERICO ESTIMULADOS CON LIPOPOLISACARIDOS. LA DETERMINACION DE LA SECUENCIA DE AMINOACIDO HA REVELADO QUE EL MPF-4 COMPARTE HOMOLOGIAS CON EL FACTOR 4 DE LAS PLAQUETAS COMENZANDO EN EL RESIDUO 17 N TERMINAL. EL CPF-4 CONSTA DE DISULFURO DE MPF-4 UNIDO A LOS 16 RESIDUOS N TERMINAL N DEL FACTOR 4 DE LAS PLAQUETAS. TANTO EL MPF-4 COMO EL CPF-4 SON POTENTES INHIBIDORES EN LA PROLIFERACION DE CELULAS ENDOTELIALES, ENTRE 10 Y 100 VECES MAS POTENTE QUE NATIVO O EL FACTOR 4 RECOMBINANTE DE LAS PLAQUETAS, HACIENDOLOS UTILES EN EL TRATAMIENTO DE ENFERMEDADES ANGIOGENICAS.
ES93307592T 1992-09-25 1993-09-24 Factor-4 plaquetario modificado. Expired - Lifetime ES2101237T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US95279792A 1992-09-25 1992-09-25

Publications (1)

Publication Number Publication Date
ES2101237T3 true ES2101237T3 (es) 1997-07-01

Family

ID=25493243

Family Applications (1)

Application Number Title Priority Date Filing Date
ES93307592T Expired - Lifetime ES2101237T3 (es) 1992-09-25 1993-09-24 Factor-4 plaquetario modificado.

Country Status (24)

Country Link
US (3) US5538949A (es)
EP (1) EP0589719B1 (es)
JP (1) JPH06220091A (es)
KR (1) KR940007059A (es)
CN (1) CN1035257C (es)
AT (1) ATE151777T1 (es)
AU (1) AU665114B2 (es)
BR (1) BR9303903A (es)
CA (1) CA2106629A1 (es)
CZ (1) CZ195193A3 (es)
DE (1) DE69309827T2 (es)
DK (1) DK0589719T3 (es)
ES (1) ES2101237T3 (es)
FI (1) FI934183L (es)
GR (1) GR3023356T3 (es)
HK (1) HK100597A (es)
HU (1) HUT69928A (es)
IL (1) IL107040A0 (es)
MX (1) MX9305901A (es)
MY (1) MY109158A (es)
NO (1) NO933423L (es)
NZ (1) NZ248724A (es)
YU (1) YU61893A (es)
ZA (1) ZA936925B (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA936925B (en) * 1992-09-25 1995-03-20 Lilly Co Eli Modified platelet factor-4.
IL113561A0 (en) * 1994-05-09 1995-08-31 Lilly Co Eli Expression of recombinant mpf-4, cpf-4, pf-4 and precursor compounds
US5994292A (en) * 1995-05-31 1999-11-30 The United States Of America As Represented By The Department Of Health And Human Services Interferon-inducible protein 10 is a potent inhibitor of angiogenesis
JPH09143199A (ja) * 1995-11-17 1997-06-03 Nippon Chem Res Kk 血小板第４因子の製造方法
CN101307106B (zh) * 1995-12-13 2013-06-12 儿童医学中心公司 内皮细胞增殖抑制剂及其应用方法
FR2774990B1 (fr) * 1998-02-16 2000-07-28 Inst Vaisseaux Et Du Sang Nouveaux peptides, utilisation en therapeutique et compositions pharmaceutiques les renfermant
US20050137167A1 (en) 2001-09-12 2005-06-23 Benito Casu Derivatives of partially desulphated glycosaminoglycans as heparanase inhibitors, endowed with antiangiogenic activity and devoid of anticoagulating effect
EP1812468A2 (en) * 2004-09-15 2007-08-01 K.U.Leuven Research & Development Platelet factor 4 variant 1 (pf4var1) related inhibitors of angiogenesis
CN114805536B (zh) * 2022-06-24 2022-09-02 北京百臻生物技术有限公司 一种人血小板因子4蛋白突变体及其应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4645828A (en) * 1984-03-23 1987-02-24 Oncogen Platelet related growth regulator
US4737580A (en) * 1985-03-15 1988-04-12 Oncogen Platelet related growth regulator
US4844895A (en) * 1985-11-01 1989-07-04 New York University Composition containing a peptide fragment of platelet factor four and method for restoring suppressed immune responses
NZ218634A (en) * 1985-12-20 1991-06-25 Oncogen Peptide identified by its cross reactivity with a cell growth factor, dna, antibodies to peptide and test kits
AU1539188A (en) * 1987-05-04 1988-11-10 Bristol-Myers Squibb Company TGF-B2 and novel compositions having anti-neoplastic activity
US5086164A (en) * 1989-01-10 1992-02-04 Repligen Corporation Novel methods and compositions for treatment of angiogenic diseases
US5187075A (en) * 1989-01-26 1993-02-16 Sri International Cloning and expression of a variant gene of platelet factor 4 and compositions thereof to modulate immune responses
US5112946A (en) * 1989-07-06 1992-05-12 Repligen Corporation Modified pf4 compositions and methods of use
EP0423641A3 (en) * 1989-10-18 1992-01-15 Nippon Mining Company Limited Expression vector, transformed microorganism, fusion protein and method for the production of platelet factor 4 or tgfalpha
EP0541716A1 (en) * 1990-07-27 1993-05-19 Repligen Corporation Novel methods and compositions for treatment of angiogenic diseases
ZA936925B (en) * 1992-09-25 1995-03-20 Lilly Co Eli Modified platelet factor-4.

Also Published As

Publication number Publication date
AU665114B2 (en) 1995-12-14
AU4757393A (en) 1994-03-31
US5935928A (en) 1999-08-10
BR9303903A (pt) 1994-06-14
US5512550A (en) 1996-04-30
NZ248724A (en) 1995-10-26
FI934183A7 (fi) 1994-03-26
GR3023356T3 (en) 1997-08-29
EP0589719A1 (en) 1994-03-30
NO933423L (no) 1994-03-28
HK100597A (en) 1997-08-08
CN1088216A (zh) 1994-06-22
ZA936925B (en) 1995-03-20
CZ195193A3 (en) 1994-04-13
HU9302687D0 (en) 1993-12-28
NO933423D0 (no) 1993-09-24
DE69309827T2 (de) 1997-08-28
CN1035257C (zh) 1997-06-25
MY109158A (en) 1996-12-31
MX9305901A (es) 1994-05-31
YU61893A (sh) 1996-02-19
DE69309827D1 (de) 1997-05-22
ATE151777T1 (de) 1997-05-15
EP0589719B1 (en) 1997-04-16
FI934183A0 (fi) 1993-09-24
FI934183L (fi) 1994-03-26
IL107040A0 (en) 1993-12-28
DK0589719T3 (da) 1997-09-08
CA2106629A1 (en) 1994-03-26
HUT69928A (en) 1995-09-28
US5538949A (en) 1996-07-23
KR940007059A (ko) 1994-04-26
JPH06220091A (ja) 1994-08-09

Similar Documents

Publication Publication Date Title
ES2094159T3 (es) Produccion de factor de crecimiento de celulas endoteliales vasculares.
FR13C0021I2 (fr) Conjugates d'exendin-4 et leur utilisation medicale
ES2127831T3 (es) Unidades de expresion multicistronicas y su aplicacion.
DK0749317T3 (da) Terapeutiske anvendelser af dimerprodukter af baktericidt/permeabilitetsforøgende protein
IT1210364B (it) Bisturi chirurgico del tipo criogenico ad ultrasuoni.
ES2095926T5 (es) Cyclosporins.
CY1108610T1 (el) Πεπτιδια της il-2 και παραγωγα αυτων και χρηση αυτων ως θεραπευτικοι παραγοντες
GR880100152A (el) Συνθεσεις για την περιποιηση της επιδερμιδος.
ATE112317T1 (de) Bcrf1-proteine als inhibitoren von interferon- g(g).
DK0383417T3 (da) Flagmusespyt-plasminogenaktivator v-PAalfa1
GR880100775A (el) Παράγοντας ενεργοποιήσεως ουδετεροφίλων.
DE3880194D1 (de) Zyklisches antikoagulierendes peptid.
DE3882279D1 (de) Zyklisches antikoagulierendes peptid.
MX9305901A (es) Factor-4 plaquetario modificado, factor-4 plaquetario de ruptura y procedimiento para la preparacionde los mismos.
PE92298A1 (es) Variantes de aprotinina con propiedades mejoradas
ES2120506T3 (es) Nuevas amidas, sulfonamidas y sulfonamidas de piperidilo utilizadas como inhibidores de la biosintesis del colesterol.
KR100488038B1 (ko) 기관 보호 활성을 지닌 신규한 신체 보호 화합물 펩티드염, 이의 제조 방법 및 치료에서의 이의 용도
IT1251961B (it) Peptidi che rappresentano permutazioni della sequenza del mastoparano
RU93013386A (ru) Протез слуховых косточек
CO4230067A1 (es) Composicion cosmetica para el cuidado de la piel
IT1216188B (it) Strumento indicatore del grado di abbronzatura dell'epidermide.
ES2147032T3 (es) Peptidos antitromboticos derivados de elementos repetidos de fibronectina tipo ii.
IT8436255U1 (it) Scarpa unisex da jogging e tempo libero aperta nella punta ed ai lati o aperta nella punta e chiusa ai lati e viceversa.
IT8283477A0 (it) Procedimento di trattamento di una sostanza proteica allo scopo di separare le proteine e i raggruppamenti prostetici, ed applicazioni all'emoglobina e alla clorofilla.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 589719

Country of ref document: ES